Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC ...Middle East

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals...

Hence then, the article about johnson johnson s tar 200 monotherapy achieves high disease free survival of more than 80 percent in bcg unresponsive high risk papillary nmibc was published today ( Saturday 26/04/2025 - 09:06 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC )

Also on site :

• Suspect in Mississippi synagogue fire laughed as he confessed to his dad, authorities say
• Fire crews and Hazmat teams responded to fire involving lithium ion batteries at Higuera Street facility
• No injuries reported after partial building collapse in the Bronx, officials say